Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Crop Life Science Ltd. (CLSL)
SME CapPharma stocks · SME cap · NSE
Crop Life Science Ltd. operates in Agrochemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result01 Jun, 07:43 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
72BullishSMA20 -20.4% / mo · MACD + · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 54
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
CLSLD candles · FIT view+59.1%Latest close ₹70.95 on 2026-10-21
Bar
+0.1%
RSI
56
MACD hist
0.83
52W pos
60%
2026-10-21O ₹70.90H ₹70.95L ₹70.90C ₹70.95Vol 6,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
CLSLNifty PharmaNifty 500
- CLSL
- +14.4%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +20.9 pp
Chart stats
21 Oct 2026- From 52W high
- -23.1%
- 52W range position
- 60%
- ATR (14)
- 4.5%
- Volume vs 20D
- 1.13x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹53.9 - ₹78.8
₹92.3
₹39.1 - ₹92.3
₹3.2
Latest completed session
20-session average
58.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST34
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average30
Revenue -10.3% · PAT +33.3% YoY
Technical
Bullish72
Price trend and sector-relative-strength timing.
Valuation
Legacy model+59.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence60
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Average · 30/100Rev -10% YoY · PAT +33% YoY · margin expansion · operating leverage
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹87 Cr | -10.3% | -27.5% |
| EBITDA | ₹10 Cr | NDF | +25.0% |
| Operating margin | 11.0% | NDF | +400 bps |
| PAT | ₹4 Cr | +33.3% | +33.3% |
| PAT margin | 4.6% | NDF | +210 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 16.80
- P/B
- 1.31
- EV/EBITDA
- 7.26
- Market Cap
- 110.00Cr
Profitability
- ROE
- 8.11%
- ROCE
- 10.80%
- ROA
- 2.88%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 16.02%
- EPS 5Y
- 14.47%
- Revenue 3Y
- 16.00%
- EPS 3Y
- 17.00%
Balance Sheet
- Debt/Equity
- 0.68
- Interest Coverage
- 3.60×
- Altman Z
- 2.39
- Book Value
- 49.20
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -8.00 Cr
- EPS TTM
- 3.87
Shareholding
- Promoter Hold
- 67.21%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 48%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 87.0-27.5% vs prev
Net Profit
₹ CrLatest: 4.0+33.3% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 56. Wait for confirmation.
- SMA20 falling (~25.7% over last month) — short-term momentum negative.
- RSI(14) at 56 — rising, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 23% off 52W high · 82% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
90
RS percentile
Stage 2 UptrendNew S2
1M return
-10.0%
3M return
+47.8%
6M return
+44.8%
1Y return
+39.1%
RS 1D
+4
RS 20D
-1
Sector rank
#1
Industry rank
-
Stage evidence
- Price is 27.2% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +4.2%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
12 Oct 2026
S2 age
5 trading sessions
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
190 observations
21 Oct 2026Value 132.87+5.93%
RS vs Nifty 500133
Valuation & peers
U-Score 34 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 34 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation19/30
Growth12/25
Quality0/20
Balance Sheet8/15
Cash Flow0/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
34
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
34/100 · legacy band WATCHLIST
Positive drivers
- Fair-value margin of safety is positive at 59.3%.
- Valuation contributes 19/30 to the score.
- Balance sheet contributes 8/15 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
16.8
PB
1.3
EV/EBITDA
7.3
ROE
8.1%
ROCE
10.8%
FCF Yield
—
Debt/Equity
0.7
MoS
+59.3%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
34
Previous: 34
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+59.3%
Previous: +61.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
40
40
40
40
40
38
36
35
35
35
34
34
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹65.45
-8.4% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹174.15
+59.3% MoS
PEG
1.09
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
BESTAGRO
Small
Best Agrolife Limited
Agrochemicals
match 148
32
21.2
1.1%
-911%
WATCHLIST
ADVANCE
Small
Advance Agrolife Limited
Agrochemicals
match 148
40
29.0
29.1%
-152%
WATCHLIST
UPL
Mid
UPL Limited
Agrochemicals
match 126
32
22.6
5.6%
-478%
WATCHLIST
RALLIS
Micro
Rallis India Limited
Agrochemicals
match 126
38
17.5
10.2%
-195%
WATCHLIST
BAYERCROP
Large
Bayer Cropscience Limited
Agrochemicals
match 125
26
327.0
15.8%
-5483%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Crop Life Science Ltd. operates in Agrochemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
60Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 28th percentile of the scored universe and 19th percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
28th percentile
overall median 67 · Pharma: 19th pctile, median 70 · SME: 32nd pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
65
acceptable · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
63
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 70%.
- ▸Promoter pledge is zero.
- ▸OPM spread across recent quarters is 4%.
Trust risks
- ▸Operating cash flow is negative at ₹-8 Cr.
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Crop Life Science Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.